United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, March 22nd. The stock was sold at an average price of $139.37, for a total transaction of $278,740.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $278,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
United Therapeutics Co. (NASDAQ:UTHR) opened at 140.05 on Monday. The company has a market cap of $6.30 billion, a P/E ratio of 9.18 and a beta of 1.42. United Therapeutics Co. has a 52 week low of $97.52 and a 52 week high of $169.89. The company has a 50-day moving average of $152.27 and a 200-day moving average of $137.20.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported $4.12 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.51. United Therapeutics had a net margin of 44.40% and a return on equity of 41.78%. The business earned $409 million during the quarter, compared to analysts’ expectations of $415.51 million. During the same quarter in the prior year, the company posted $3.80 EPS. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, equities research analysts predict that United Therapeutics Co. will post $14.13 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Tommy G. Thompson Sells 2,000 Shares of United Therapeutics Co. (UTHR) Stock” was originally posted by Mideast Time and is owned by of Mideast Time. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.mideasttime.com/tommy-g-thompson-sells-2000-shares-of-united-therapeutics-co-uthr-stock/1589120.html.
Several hedge funds have recently bought and sold shares of UTHR. Mason Street Advisors LLC purchased a new stake in United Therapeutics during the second quarter valued at $2,155,000. Oregon Public Employees Retirement Fund boosted its stake in United Therapeutics by 39.6% in the third quarter. Oregon Public Employees Retirement Fund now owns 26,223 shares of the biotechnology company’s stock valued at $3,096,000 after buying an additional 7,441 shares during the period. Fisher Asset Management LLC boosted its stake in United Therapeutics by 1.0% in the third quarter. Fisher Asset Management LLC now owns 3,124 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 32 shares during the period. Creative Planning boosted its stake in United Therapeutics by 40.2% in the third quarter. Creative Planning now owns 3,379 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 969 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in United Therapeutics during the third quarter valued at $496,000.
Several analysts have recently weighed in on the stock. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 14th. Wedbush reaffirmed an “outperform” rating and set a $229.00 price target on shares of United Therapeutics in a research note on Wednesday, February 8th. Standpoint Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 19th. Zacks Investment Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 17th. Finally, Jefferies Group LLC downgraded shares of United Therapeutics from a “hold” rating to an “underperform” rating and decreased their price target for the company from $149.47 to $116.00 in a research note on Monday, March 6th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. United Therapeutics currently has an average rating of “Hold” and an average target price of $138.31.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.